Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — Merger or Acquisition (October 2019)
7 slides from Zealand Pharma A/s's merger presentation, Oct 23, 2019
Slide 1: Strengthening our leadership in peptide therapeutics and novel treatments for gastrointestinal diseases
Strengthening our leadership in peptide therapeutics and novel treatments for gastrointestinal diseases Strategic pipeline expansion Growing the Zealand Pharma peptide platform technology with a unique oral Leveraging R&D expertise Utilizing Zealand Pharma’s world-leading capabilities in peptide dev
Slide 2: Financially compelling strategic transaction
Financially compelling strategic transaction 100% Contingent Consideration No upfront payment Key Figures Future potential earn-outs of up to US $80 million contingent on successful achievement of development, regulatory and commercial milestones • Of which, US $10 million would be payable by succes
Slide 3: Lead asset: ET3764, an α4β7 integrin inhibitor
Lead asset: ET3764, an 47 integrin inhibitor Integrin 47 is involved in migration of pro-inflammatory lymphocytes from blood to inflamed intestinal tissue through interactions with MAdCAM-1 ET3764 inhibits this interaction by binding to the interaction site on 47 Target is clinically validated by ve
Slide 4: Gaining access to library of some 5,000 peptide macrocycles
Gaining access to library of some 5,000 peptide macrocycles In addition to acquiring the lead target, Zealand gains access to a screening library of some 5,000 peptide macrocycles The library is based on short peptide or peptide-like molecules made cyclic using proprietary chemistry technology These
Slide 5: On a clear path toward achieving Zealand Pharma's strategic objectives
On a clear path toward achieving Zealand Pharma’s strategic objectives Strategic pipeline expansion of the Zealand Pharma peptide platform a unique oral peptide technology with Leveraging Zealand Pharma’s R&D expertise in peptide development Making a financially compelling strategic transaction • •
Slide 6: Q&A / Upcoming Investor Events
Q&A Upcoming Investor Events Bryan Garnier 7th Annual European Healthcare November 12, 2019, Paris Conference Zealand Pharma Interim Report for Q3 2019 November 14, 2019, Copenhagen Jefferies 2019 Healthcare Conference November 20, 2019, London Økonomisk Ugebrev November 27, 2019, Life Science Inves
Slide 7: Q&A / Upcoming Investor Events
ZEAL oie Q&A~- ZEALAND PHARMA | oa Upcoming Investor Events pws Bryan Garnier 7‘* Annual European Healthcare Conference r November 12, 2019, Paris Ea] Zealand Pharma Interim Report for Q3 2019 November 14, 2019, Copenhagen Jefferies 2019 Healthcare Conference November 20, 2019, London @konomisk Ugeb
Zealand Pharma — Merger or Acquisition (October 2019) on 6ix